GSK Committed To Phase II COX-2 Inhibitor Regardless Of FDA Cmte. Outcome
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline will continue development of its Phase II COX-2 inhibitor regardless of the outcome of an FDA advisory committee meeting on the safety of the class, CEO J.P. Garnier told investors